Introduction
The Insulin-like growth factor (IGF) system comprises two IGFs (IGF-I and IGF-II), IGF-I and IGF-II receptors, and at least six distinct insulin-like growth factor binding proteins (IGFBPs) 30 . In the central nervous system, IGF-I and IGF-II support the growth and differentiation of neurons and glial cells 3, 12 . The distribution of IGF-I and, IGF-II receptors have been studied in both rodent and human brains 8, 13, 16, 18, 36 . The IGF-I receptor is a heterotetrameric glycoprotein composed of two alpha and two beta subunits linked by disulphide bounds 12 . The IGF-II receptor is a monomeric receptor with a striking extracellular domain made up almost exclusively of 15 cysteine-based repeats, and is identical to the cation-independent mannose-6-phosphate receptor 17, 23 .
IGFBPs play a crucial role in transporting IGFs in the circulation, cerebrospinal fluid, and across the capillary barrier to the target cells 7, 26 . IGFBP-3 and IGFBP-5, in addition to binding IGFs, also can associate with an acid-labile subunit (ALS), thereby further increasing the half-life of the IGFs 33, 34 . IGFBPs are also present at the level of the extracellular matrix or cell surface, where they can either enhance or inhibit the presentation of IGFs to their receptors 10, 14, 25, 30 .
In addition, some of the IGFBPs, such as IGFBP-3, are also capable to mediate biological actions that are IGF independent 10, 25, 30 . More recently, a family of IGFBP-related proteins (IGFBP-rPs) has been identified that appear to have a 100-fold lower affinity for IGFs, compared with the IGFBPs. The functional roles of these IGFBP-rPs remain at present elusive 14 . This study was undertaken to characterise the cell membrane-bound binding sites for IGF-I in human brain and pituitary gland. Normal rabbit serum was purchased from Zymed (San Francisco, CA, USA 
Material and methods

Materials
Specificity of the antibodies
The antibody against human IGF-I receptor reacts specifically against a 19-residue synthetic peptide corresponding to amino acid residues (642-659) of the human IGF-I receptor alphasubunit 27 . The polyclonal IGFBP-3 antibody used in this study was obtained from rabbits immunised with a synthetic peptide of unique sequence from the central domain of human IGFBP-3. The specificity of the antibody was confirmed using the antibody preabsorbed with excess of matched recombinant human IGFBP-3. Specificity of the immunoreactivity was also controlled by the incubation of tissue sections in 5 % goat serum instead of primary antibodies; the immunohistochemical reactions were negative. For Western-blotting experiments, non-specific staining was determined by incubating parallel blots with nonimmune rabbit serum instead of the primary antibody solution ( Figure 4B ). For immunoprecipitation experiments, non-specific binding was determined by incubating parallel blots with 3 % bovine serum albumin (BSA) instead of the primary antibody solution. The non-specific binding of the anterior pituitary is shown in Figure 5 . The non-specific bands for serum and other brain samples were the same (not shown).
Tissues
Brains and pituitary glands were obtained from 10 patients without neurological or psychiatric diseases (five men and five women, ages between 54 and 78 years). Pituitary glands and 0.5-cm thick blocks of brain tissue were dissected at 0-4°C, frozen rapidly by immersion in isopenthane-dry-ice, and stored at -80°C until used. Frontal cortex and white matter was obtained from the frontal gyri and cerebellum from one of the hemispheres. Care was taken to dissect comparable regions from the different individuals. The choroid plexus was obtained from the lateral ventricles. Post mortem delay, defined as the time elapsed between death and freezing of the tissue sections, ranged between 7 and 14 hours. An Ethical
Committee approved the experiments on post-mortem brain.
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Frozen tissue blocks were mounted on a cryostat chuck, coated with embedding medium (OCT compound, Lab-Tek Products, Ontario, Canada) and serial sections, 10-µm thick, were cut at -20°C using a microtome-cryostat. Thereafter, sections were mounted on gelatine- 
Preparation of homogenates
Frozen tissue blocks of approximately 1 g were homogenised in 10 ml ice-cold Tris/HCl buffer (25 mM, pH 7.4) containing serine-, cysteine-, aspartic-and metallo-proteinases inhibitors,
with an Ultraturrax and Potter Elvehjem homogeniser, and centrifuged at 50,000 g for 15 min.
The pellets, containing the cell membranes, were resuspended in 10 ml of the same buffer as indicated above and centrifuged twice at 50,000 g for 15 min. The final pellet was suspended in 1 ml of the same buffer containing 10 % glycerol (vol/vol), and stored at -80ºC. Protein concentrations were determined by the method of Lowry et al 20 . To be sure that there is no blood contamination from the circulation, albumin was measured in homogenates from the anterior and posterior pituitary gland by using an albumin immune assay (BN2, Behring, Gmbh, Marburg, Germany). In all the samples we used in this study the albumin fraction was not detectable.
Western-immunoblotting and immunoprecipitation
For Western-immunoblotting experiments the homogenates were diluted and resolved in Between all steps the nitrocellulose membrane was rinsed in TBS for 30 min.
Immunohistochemical experiments
Frozen sections, 10-µm thick were preincubated in 25 mM Tris/HCl (pH 7.4) containing 10 mM MgCl 2 . Sections that were and were not preincubated were fixated in 3 % buffered formaldehyde for 15 minutes and washed in PBS for 10 minutes. To exhaust endogenous peroxidase activity, sections were immersed for 10 min in 0. and they were counterstained with 3% hematoxylin. Between all steps the sections were rinsed thoroughly with PBS.
RT-PCR experiments
HepG2-cells were cultured in DMEM supplemented with 10% foetal calf serum, 50 U/ml penicillin, and 50 µg/ml streptomycin in a humidified 5% CO 2 atmosphere at 37°C. Total (antisense, 770 bp amplified product). In each experiment, water, RNA, and cDNA alone as well as cDNA with only sense or antisense primer was used as a negative control to check for contamination and specificity. Ten microlitres of PCR products were separated on 2.0% agarose gels, stained with ethidium bromide, and photographed using a Polaroid DS34 Instant Screen Direct Camera (Hertfordshire, UK).
Results
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IGF-I receptor and IGFBP-3-binding in homogenates from human pituitary and brain regions
To Western blotting was performed under different conditions. In the first approach pellet fractions of the anterior pituitary ran under denaturing and reducing conditions, and were stained for IGFBP-3. A single band of 40-kDa ( Figure 4A ) was detected under these conditions. When the same samples ran under native conditions, and were stained for IGFBP-3 they revealed one band of 150-kDa ( Figure 4A ). Purified IGFBP-3 was used as a positive control. With anti-IGFBP-3 we found one band of 40-kDa ( Figure 4A ). Non-immune rabbit serum was used to determine the non-specific binding ( Figure 4B ).
We performed immunoprecipitation experiments to visualise the components of the complex. The same band was present in human serum that contains ALS and was used as a positive control. This was not observed in the frontal cortex and the posterior pituitary ( Figure 5 ).
Thus these results showed the presence of an IGFBP-3-ALS complex in the anterior pituitary. This complex was absent in the posterior pituitary and frontal cortex.
Figure 4
Western-immunoblots of anterior pituitary samples ran on 12 % SDS-PAGE both under native conditions, and under reducing and denatured conditions. Samples were stained for IGFBP-3 (A).
Samples ran under native conditions revealed a 150-kDa-band (i) and samples that ran under reducing conditions revealed a single band of 40-kDa (ii). Human IGFBP-3 was used as a positive control and presents one band of 40-kDa (iii). In figure B, non-specific binding was determined by incubating parallel blots with non-immune rabbit serum instead of anti-IGFBP-3. Samples ran under native conditions (i), denatured conditions (ii), and pure IGFBP-3 (iii) didn't reveal nonspecific bands. Protein marker is shown at the left. Bands were visualised using opti-4CN. It has been shown previously that IGFBP-3 has cellular effects that are independent of IGF presence or action, and these effects are mediated by binding of IGFBP-3 to the cell surface, possibly to specific receptors 22, 25, 38 . However, since IGF-I in association with IGFBP-3 prevents binding of IGFBP-3 to the cell membrane 29 , the IGFBP-3 binding site in the anterior pituitary must be of a different composition.
The molecular weight of IGFBP-3 in its non-glycosylated form is 29-kDa, in its glycosylated state 40 -44-kDa, and when it forms a complex with ALS, 140 -150-kDa 21, 30 . IGFBP-3 is the predominant carrier protein of IGF-I in serum. The IGF-I:IGFBP-3 dimer forms a complex with ALS, and this ternary complex prolongs the serum half-live of IGF-I by many hours 15, 25, 30 . Once released from the complex, IGF-I leaves the circulation and enters target tissues with the aid of IGFBPs present on the cell surface or in the extracellular matrix.
By using RT-PCR in anterior pituitary and blood samples, we found the expression of ALS mRNA in the anterior pituitary and not in blood samples. Thus, our findings suggest that the human anterior pituitary gland expressed ALS mRNA and ALS protein and these ALS forms a complex with IGFBP-3 bound to the cell membrane. ALS is mainly synthesised by the liver and the native ALS molecule appears in serum as an 84 -86-kDa glycoprotein doublet 4, 5, 6, 28 .
Interestingly, it has been shown that follicular fluid ALS originates from the ovary and that ALS is also synthesised by the kidney 11, 35 .
We were unable to detect IGF-I receptors in the anterior pituitary gland in this study.
However, our in situ observations do not entirely exclude their presence in vivo. IGF-I receptor mRNA has been demonstrated by in situ hybridisation in rodent anterior pituitary slices and cell cultures 1, 24 . It might be possible that the receptors were down regulated by IGF-I, as has been shown for IGF-I receptors in rat pituitary cells 37 .
In conclusion, our findings show that in human anterior pituitary gland IGF-I binds to a not previously reported tightly membrane-bound IGFBP-3-ALS complex. The functional implication of the binding of IGF-I to this complex requires further experimentation at the cellular level.
